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Purpose: Dipeptidyl peptidase (DPP)-4 inhibitors
are an increasingly used antihyperglycemic therapy for
patients with type 2 diabetes mellitus (T2DM). Lina-
gliptin, an orally administered DPP-4 inhibitor, has
demonstrated favorable efﬁcacy/safety in clinical tri-
als. The aim of this post hoc pooled analysis was to
expand current knowledge of the safety of linagliptin.
Methods: Safety data for once-daily linagliptin 5
mg (1 study of linagliptin 2.5 mg twice daily) were
analyzed from 22 randomized, double-blind, Phase I–
III, placebo-controlled clinical trials of r102 weeks’
duration. Assessments of pooled data included inci-
dence of patient-reported adverse events (AEs).
Findings: Data from 7400 patients (linagliptin,
4810; placebo, 2590) were pooled. Most patients
(58.4%) had T2DM diagnosis for 45 years; approx-
imately 75% were receiving Z1 type of background
therapy in addition to linagliptin/placebo. Overall
exposure to the study drug was 2412.8 years for
linagliptin and 1481.4 years for placebo (mean [SD],
183 [120] days and 209 [150] days, respectively).
Overall frequencies of AEs were similar for linagliptin-
and placebo-treated patients (57.3% and 61.8%,
respectively). The incidence of neoplastic AEs was
low (0.6% and 0.9%, respectively); there were no
reports of pancreatic neoplasia. Pancreatitis was ob-
served in 2 linagliptin-treated patients (o0.1%) and 1
placebo-treated patient (o0.1%). The occurrence of
cardiac disorder AEs was similar in linagliptin- and
placebo-treated patients (3.2% [n ¼ 153] and 3.3%
[n ¼ 83], respectively); the incidence of heart failure
AEs for linagliptin- and placebo-treated patients was
0.2% (n ¼ 11) and 0.3% (n ¼ 7), respectively.1130Overall, linagliptin was weight neutral. Occurrence
of investigator-deﬁned hypoglycemic AEs was low for
both linagliptin and placebo (11.5% vs 14.0%). In
patients receiving concomitant sulfonylurea therapy,
investigator-deﬁned hypoglycemic AEs were more fre-
quent with linagliptin versus placebo (22.1% [238/
1079] vs 14.5% [61/421], respectively). Subgroup
analyses showed similar frequencies of AEs for lina-
gliptin- and placebo-treated patients across different
age groups and renal function levels.
Implications: This updated and expanded pooled,
post hoc analysis of 22 placebo-controlled trials of
linagliptin 5 mg daily supports previous ﬁndings of the
acceptable overall safety/tolerability proﬁle of lina-
gliptin when administered to a broad range of patients
with T2DM. Linagliptin-treated patients demon-
strated a low overall risk of hypoglycemia (risk
increased by concomitant sulfonylurea therapy). As
with all pooled analyses, this study is limited by the
use of data from different studies, and the relatively
short duration of some included studies, although use
of individual patient data from consistently designed
trials should minimize methodological differences
between trials. Results from ongoing clinical trials
will provide additional insight into the long-term
safety/tolerability of linagliptin. (Clin Ther.
2014;36:1130–1146) & 2014 The Authors. Published
by Elsevier HS Journals, Inc.Volume 36 Number 8
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INTRODUCTION
The growing global burden of type 2 diabetes mellitus
(T2DM) has led to an ongoing search for treatments
that demonstrate both efﬁcacy and safety in the
management of this chronic condition. Dipeptidyl
peptidase (DPP)-4 inhibitors are becoming important
oral antihyperglycemic agents, a recommended ther-
apeutic option when glycemic control cannot be
achieved with metformin or ﬁrst-line therapy where
metformin is contraindicated.1 Treatment with DPP-4
inhibitors leads to improvements in glycemic control,
with a low risk of hypoglycemia, if used in combina-
tion with agents that are not associated with an
increased risk of hypoglycemia during monotherapy.2
Linagliptin is a once-daily, orally administered DPP-
4 inhibitor with a xanthine-based structure3,4 and
exhibits high-afﬁnity binding to DPP-4 in plasma and
tissues,5 resulting in only a small fraction of the drug
being unbound. These features account for the long
terminal half-life (4100 hours) and nonlinear pharma-
cokinetic proﬁle of linagliptin.4,6,7 One clinically
important feature is its largely nonrenal route of
elimination (80% hepatic vs 5% renal),6,8,9 which
means that, in contrast to most other DPP-4 inhib-
itors,10 dose adjustment of linagliptin is not required in
patients with renal impairment.11 The glucose-lowering
efﬁcacy of linagliptin is based on its impact on the
incretin hormones, active glucagon-like peptide (GLP)-
1, and gastric inhibitory peptide (GIP), which are
secreted from the intestine after a meal. In the presence
of hyperglycemia, these hormones promote glucose-
dependent insulin secretion and reduce glucagon secre-
tion.12 Both active GLP-1 and GIP are rapidly inacti-
vated through cleavage by DPP-4.13 Thus, the
antihyperglycemic activity of linagliptin results from
enhancement of the incretin effect. Inhibition of DPP-4
by linagliptin leads to an approximately 3-fold increase
in active GLP-1 levels,14,15 resulting in improvements in
glycemic control in patients with T2DM.
Linagliptin has been evaluated in a clinical Phase I–
III trial program in 440 countries and established a
low overall rate of adverse events (AEs) that is similar
to placebo, including a low incidence of hypoglycemia
and a weight-neutral effect.16–19 Several of the trials
had a duration of 1 year or longer.20–22 In 2012, aAugust 2014pooled analysis of linagliptin safety data from 8
randomized, double-blind, placebo-controlled Phase
III clinical trials lasting r24 weeks demonstrated that
linagliptin was well tolerated.23
The aim of the present post hoc analysis is to
update the safety proﬁle for linagliptin with all
currently available placebo-controlled trials, now in-
cluding clinical trials with a duration of as long as 102
weeks. The rationale for including only placebo-
controlled trials was to avoid as much as possible
confounding by the safety proﬁles of comparator
therapies on the occurrence of AEs in the comparator
arm. This analysis also includes an assessment of
safety in 2 vulnerable patient populations—the elderly
and patients with renal impairment.
PATIENTS AND METHODS
Patient Population
Safety data for once-daily linagliptin 5 mg (and 1
study [NCT01012037] that included patients receiving
2.5 mg twice daily) were analyzed for patients who
participated in 1 of 22 randomized, double-blind, Phase
I–III placebo-controlled clinical trials of up to 102
weeks’ duration.4,7,16–19,24–40 All studies were con-
ducted in accordance with Good Clinical Practice guide-
lines and the principles of the Declaration of Helsinki.
Assessments
Safety and tolerability assessments included the
incidence and severity of patient-reported AEs. These
AEs were recorded by investigators and coded using
the Medical Dictionary for Regulatory Activities
(MedDRA) Version 15.1 as preferred terms grouped
under individual system organ classes. Investigator-
deﬁned hypoglycemic AEs were based on both clinical
symptoms and laboratory measurement of plasma
glucose levels (as deﬁned in the legend to Figure).
Electrocardiograms, physical examinations, vital signs,
and clinical and laboratory parameters were also
reported. All laboratory assessments were performed
by central laboratories.
Patient-level safety data were analyzed for the over-
all population and for subgroups based on age (o65,
65 to o75, and Z75 years), renal function (estimated
glomerular ﬁltration rate o60, 60 to o90, and Z90
mL/min/1.73 m2, as determined by the Modiﬁed Diet
in Renal Disease study equation), concomitant sulfo-
nylurea (SU) treatment, and body mass index (o25, 25
to o30, and Z30 kg/m2).1131
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Figure. Percentage of patients with investigator-defined hypoglycemic adverse events. In the overall population
(A), with or without concomitant sulfonylurea therapy (B), by age (C), and by renal function (dataset:
patients treated with linagliptin 5 mg once daily or placebo and with data on estimated glomerular
filtration rate [eGFR] [Modified Diet in Renal Disease] [N ¼ 7375]) (treated set) (D). Hypoglycemic
episodes were classified by investigators as asymptomatic if not accompanied by typical symptoms of
hypoglycemia but with a measured plasma glucose concentration r3.9 mmol/L (r70 mg/dL),
documented symptomatic when a measured plasma glucose concentrationZ3.0 mmol/L (Z54 mg/dL)
andr3.9 mmol/L (r70 mg/dL) was accompanied by typical symptoms of hypoglycemia, documented
symptomatic when a measured plasma glucose concentration o3.0 mmol/L (o54 mg/dL) was
accompanied by typical symptoms of hypoglycemia without the need for external assistance, or severe
when the assistance of another person was required to actively administer carbohydrate, glucagon, or
other resuscitative actions. 95% CI, Fisher exact test P value. RR ¼ relative risk.
Clinical TherapeuticsData Analysis
Analyses were conducted on individual patient data
in the treated set (TS), which was deﬁned as all
patients who received at least 1 dose of the study
drug. Data obtained after initiation of glycemic rescue
were also included in the analysis.
Pooled safety data were analyzed using descriptive
statistical methods to calculate AE incidence rates for
the overall population and for the patient subgroups
of interest. In an exploratory analysis, we assessed the
inﬂuence of treatment on investigator-deﬁned hypo-
glycemic AEs (for full deﬁnition, see the legend to
Figure) overall and for the following categories of age,1132renal function, and use of SU expressed as relative risk
with the corresponding 95% CIs. No other inferential
statistical tests were conducted.
RESULTS
Patient Disposition, Baseline Characteristics,
and Exposure
This post hoc pooled analysis included patients
from all currently available placebo-controlled trials,
for which data for both linagliptin and placebo groups
on matched background therapy were available: a
total of 7400 patients, of whom 4810 received
linagliptin and 2590 received placebo (Table I).Volume 36 Number 8
M. Lehrke et al.Patients in the linagliptin- and placebo-treated
groups had similar baseline demographic and clinical
characteristics (Table II). For the overall dataset,
the mean (SD) age was 58.5 (10.6) years, mean
(SD) baseline glycosylated hemoglobin was 8.2%
(0.9), and mean (SD) fasting plasma glucose was
9.1 mmol/L (2.5) (164.5 mg/dL [45.5]). The majority
of patients (58.4%) had a diagnosis of T2DM for
over 5 years. Approximately 13% of patients had a
history of coronary artery disease at baseline (12.1%
in the linagliptin group and 14.7% in the placebo
group), and nearly two thirds were hypertensive
(61.5% and 63.1%, respectively). Almost three
fourths of patients were receiving antihypertensive
therapy at the start of the trial (60.7% and 63.9%,
respectively), the most frequent antihypertensive
therapy being angiotensin-converting enzyme inhib-
itors (26.1% and 28.4%, respectively), and almost
half were receiving lipid-lowering drugs (41.5% and
45.3%, respectively). Heart failure was present in a
small minority of patients at baseline (1.5% and
1.6%, respectively). More than one fourth of patients
had microvascular disease at baseline (26.1% and
31.0%, respectively).
During therapy, 1136 (23.6%) of linagliptin- and
650 (25.1%) of placebo-treated patients received no
background antidiabetes medication; 75% of the
pooled population were receiving Z1 type of back-
ground therapy in addition to linagliptin or placebo.
The most frequent background therapies (alone
or with other antidiabetes therapies) were insulin,
SU, and metformin (patients receiving Z1 back-
ground therapy could be included in Z1 count)
(Table II): a total of 1614 patients (21.8%) were
receiving background treatment with insulin, 1500
(20.3%) were receiving SU therapy, and 4359
(58.9%) were receiving metformin. During the trial,
more patients in the placebo group were receiving
insulin background therapy (31.0%) than in the
linagliptin group (16.9%), whereas more patients in
the linagliptin group were receiving background SU
therapy (22.4%) than in the placebo group (16.3%)
(Table II).
Overall exposure to the study drug was 2412.8
years for the linagliptin group and 1481.4 years for
placebo (mean [SD], 183 [120] days and 209 [150]
days, respectively). Nearly two thirds of patients
received treatment for at least 24 weeks (3117
[64.8%] and 1670 [64.5%], respectively).August 2014Adverse Events
Overall frequencies of AEs were similar in linaglip-
tin- and placebo-treated patients, with or without
background treatment (57.3% and 61.8%, respec-
tively) (Table III). The frequencies of serious AEs were
also similar for linagliptin- and placebo-treated pa-
tients (4.8% and 6.4%, respectively) as were drug-
related AEs (11.7% and 13.7%, respectively).
All AEs that occurred with a frequency of 42%
for either linagliptin- or placebo-treated patients
(or were AEs of interest) are shown in Table IV.
The incidence of all infection and infestation AEs
observed with linagliptin was 21.3% versus 25.0%
with placebo, with nasopharyngitis reported in 5.8%
and 6.0% of patients treated with linagliptin and
placebo, respectively. Gastrointestinal disorders occurred
in 11.4% of linagliptin- and 12.7% of placebo-treated
patients; with similar incidences irrespective of whe-
ther patients were receiving no oral background
therapy (linagliptin, 10.5% and placebo, 11.3%) or
receiving concomitant therapy such as metformin or
SU (linagliptin, 11.6% and placebo, 13.3%). Diarrhea
was the only gastrointestinal AE that occurred at a
frequency of Z2% (2.7% and 3.0% for linagliptin-
and placebo-treated patients, respectively).
The overall incidence of neoplasia (benign and malig-
nant) was low –0.6% for linagliptin- and 0.9% for
placebo-treated patients— and there were no reports of
pancreatic neoplasia (Table IV). In the trials included in
this analysis, pancreatitis was observed in 2 linagliptin-
treated patients (o0.1%) and 1 placebo-treated patient
(o0.1%). Corresponding ﬁgures for chronic pancreatitis
were 3 patients (0.1%) in the linagliptin group, who
reported exacerbation of pre-existing chronic pancreati-
tis, and none for patients receiving placebo. The pan-
creatitis episodes reported in the linagliptin group were
all mild or moderate in intensity, and the episode
reported for the patient receiving placebo was severe;
none of the pancreatitis cases were fatal. Three of the 5
patients with recorded episodes of pancreatitis in the
linagliptin group had episodes that were recorded as
nonserious, whereas 2 additional patients required hos-
pitalization; the patient with an episode of pancreatitis in
the placebo group also required hospitalization. In-
creased blood amylase levels were reported in a similar
proportion of linagliptin-treated patients (14 patients,
0.3%) and placebo-treated patients (4 patients, 0.2%).
The overall incidence of cardiac disorders was
similar for linagliptin- and placebo-treated patients1133
Table I. Randomized, double-blind, placebo-controlled trials included in this pooled analysis.
ClinicalTrials.gov
Registration
Number Background Treatment Treatment Arms*
Duration
(wk)
Mean
Age (y)
Men
(%)
White/
Asian (%) Reference
None Linagliptin 1 mg once daily, n ¼ 9
Linagliptin 2.5 mg once daily, n ¼ 9
Linagliptin 5 mg once daily, n ¼ 8
Linagliptin 10 mg once daily, n ¼ 9
Placebo, n ¼ 12
o2 56 100 100.0/0 Heise et al4
None Linagliptin 2.5 mg once daily, n ¼ 26
Linagliptin 5 mg once daily, n ¼ 16
Linagliptin 10 mg once daily, n ¼ 19
Placebo, n ¼ 16
4 62 94 100.0/0 Forst et al7
NCT00328172 None Linagliptin 0.5 mg once daily, n ¼ 58
Linagliptin 2.5 mg once daily, n ¼ 57
Linagliptin 5 mg once daily, n ¼ 55
Placebo, n ¼ 67
Metformin, n ¼ 65
12 57 57.9 90.1/3.6 Singh-Francot et al30
NCT00309608 Metformin (most
received Z1500 mg/d)
Linagliptin 1 mg once daily, n ¼ 65
Linagliptin 5 mg once daily, n ¼ 66
Linagliptin 10 mg once daily, n ¼ 66
Placebo, n ¼ 71
Glimepiride 1–3 mg once daily, n ¼ 65
12 60 58.0 99.0/1.0 Forst et al29
NCT00641043 None Linagliptin 5 mg once daily þ pioglitazone
30 mg once daily, n ¼ 259
Placebo þ pioglitazone 30 mg once daily,
n ¼ 130
24 57.5 60.9 74.6/24.9 Gomis et al17
NCT00621140 None Linagliptin 5 mg once daily, n ¼ 336
Placebo, n ¼ 167
24 55.7 48.3 53.7/46.1 Del Prato et al16
NCT00601250 Metformin (Z1500 mg/d or
maximal tolerated dose)
Linagliptin 5 mg once daily, n ¼ 523
Placebo, n ¼ 177
24 56.5 54.1 76.1/20.9 Taskinen et al19
NCT00602472 Metformin (Z1500 mg/d or maximal
tolerated dose) þ sulfonylurea
Linagliptin 5 mg once daily, n ¼ 792
Placebo, n ¼ 263
24 58.1 47.2 46.6/51.7 Owens et al18
NCT00654381 None Linagliptin 5 mg once daily, n ¼ 159
Linagliptin 10 mg once daily, n ¼ 160
Voglibose 0.2 mg TID, n ¼ 162
Placebo, n ¼ 80
12† 60.0 70.4 0.0/100.0 Kawamori et al25
NCT00819091 Sulfonylurea Linagliptin 5 mg once daily, n ¼ 157
Placebo, n ¼ 81
18 56.9 52.7 43.7/48.6 Lewin et al26,‡
NCT00954447 Basal insulin alone or in combination
with metformin and/or pioglitazone
Linagliptin 5 mg once daily, n ¼ 628
Placebo, n ¼ 627
52§ 59.7 52.2 N/A Yki-Järvinen et al31,‡
NCT00716092 None Linagliptin 5 mg once daily, n ¼ 40
Sitagliptin 100 mg, n ¼ 41
Placebo, n ¼ 40
4 61.1 50.5 N/A Rauch et al28
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Table I. (continued).
ClinicalTrials.gov
Registration
Number Background Treatment Treatment Arms*
Duration
(wk)
Mean
Age (y)
Men
(%)
White/
Asian (%) Reference
NCT00800683 Existing glucose-lowering background
therapy
Linagliptin 5 mg once daily, n ¼ 67
Placebo, n ¼ 63
52 64.4 60.2 73.7/14.3 McGill et al32,‡
NCT00798161 None Linagliptin 5 mg once daily, n ¼ 142
Metformin 500 mg BID, n ¼ 144
Linagliptin 2.5 mg BID þ metformin 500
BID, n ¼ 143
Metformin 1000 mg BID, n ¼ 147
Linagliptin 2.5 mg BID þ metformin 1000
BID, n ¼ 143
Placebo, n ¼ 72
24 55.3 57.1 66.8/32.5 Haak et al40
NCT00740051 None Linagliptin 5 mg once daily, n ¼ 151
Placebo, n ¼ 76
18 56.5 38.8 70.6/27.4 Barnett et al24
NCT00996658 Metformin þ pioglitazone Linagliptin 5 mg once daily, n ¼ 183
Placebo, n ¼ 89
24 53.8 48.5 31.2/68.8 Bajaj et al33
NCT01012037 Metformin (Z1500 mg/d or maximal
tolerated dose)
Linagliptin 2.5 mg BID, n ¼ 223
Linagliptin 5 mg once daily, n ¼ 224
Placebo, n ¼ 44
12 58.6 57 65.4/33.8 Ross et al34
NCT01084005 Metformin and/or sulfonylurea and/or
basal insulin
Linagliptin 5 mg once daily, n ¼ 162
Placebo, n ¼ 79
24 74.9 68.5 96.7/2.1 Barnett et al35
NCT01087502 Existing glucose-lowering background
therapy
Linagliptin 5 mg once daily, n ¼ 113
Placebo, n ¼ 122 (weeks 1–12, then
switched to glimepiride, 1–4 mg once daily
until week 52)
52 67 N/A N/A Laasko et al36
NCT01215097 Metformin Linagliptin 5 mg once daily, n ¼ 205
Placebo, n ¼ 100
24 55.5 49.8 0.0/100.0 Wang et al38
NCT01214239 None Linagliptin 5 mg once daily, n ¼ 200
Placebo, n ¼ 99
24 N/A N/A 0/100 Chen et al37
NCT01194830 Existing glucose-lowering background
therapy
Linagliptin 5 mg once daily, n ¼ 101
Placebo, n ¼ 115
24 54 54 0/0 Thrasher et al39,‡
N/A ¼ not available; BID ¼ twice daily; TID ¼ three times daily.
*Only data from the treatment arms shown in bold were included in the pooled safety analysis reported here.
†The study duration was a total of 52 weeks, comprising an initial 12-week, placebo-controlled, double-blind phase, followed by a further 14 weeks of double-blind, active-
controlled treatment, and then a 26-week open-label extension; data shown are from patients receiving linagliptin 5 mg or placebo in the initial 12 weeks of treatment.
‡Results from certain centers were later excluded due to serious noncompliance.
§The study duration was at least 52 weeks. Patients who had been randomly assigned early in the study were to be treated for longer than 52 weeks until the study close out,
which was to occur as soon as all patients had been treated for at least 52 weeks.
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Table II. Baseline demographic and clinical characteristics for pooled patients (TS).
Linagliptin Placebo
No. of patients 4810 2590
Sex, no. (%)
Male 2575 (53.5) 1427 (55.1)
Female 2235 (46.5) 1163 (44.9)
Race, no. (%)
White 2729 (56.7) 1537 (59.3)
Black 193 (4.0) 188 (7.3)
Asian 1888 (39.3) 865 (33.4)
Age, y 58.3 (10.6) 58.8 (10.5)
Age groups, y, no. (%)
r50 1082 (22.5) 546 (21.1)
51–65 2307 (48.0) 1243 (48.0)
65 to o75 1153 (24.0) 647 (25.0)
Z75 268 (5.6) 154 (5.9)
Weight, kg 79.6 (18.3) 82.0 (18.4)
Baseline BMI, kg/m2 29.1 (5.2) 29.7 (5.3)
Baseline BMI, kg/m2, no. (%)
o30 2946 (61.2) 1444 (55.8)
Z30 1864 (38.8) 1146 (44.2)
Baseline eGFR (MDRD staging), mL/min, no. (%)
Z90 1918 (39.9) 955 (36.9)
60 to o90 2263 (47.0) 1198 (46.3)
30 to o60 508 (10.6) 310 (12.0)
o30 111 (2.3) 112 (4.3)
Missing 10 (0.2) 15 (0.6)
Baseline HbA1c, %
* 8.17 (0.88) 8.20 (0.90)
Fasting plasma glucose, mmol/L* 9.1 (2.5) 9.2 (2.6)
Fasting plasma glucose, mg/dL 164.2 (44.7) 165.1 (47.1)
Duration of diabetes, y, no. (%)
r1 631 (13.1) 292 (11.3)
41 to r5 1440 (29.9) 701 (27.1)
45 2731 (56.8) 1590 (61.4)
Missing 8 (0.2) 7 (0.3)
Relevant medical history at baseline, no. (%)
Coronary artery disease 583 (12.1) 381 (14.7)
Cerebrovascular disease 187 (3.9) 130 (5.0)
Congestive heart failure 73 (1.5) 41 (1.6)
Hypertension 2958 (61.5) 1635 (63.1)
Microvascular disease† 1255 (26.1) 804 (31.0)
Patients receiving CV medication at baseline, no. (%)‡
Antihypertensives 2920 (60.7) 1654 (63.9)
ACE inhibitors 1254 (26.1) 736 (28.4)
ARBs 717 (14.9) 398 (15.4)
β-Blockers 952 (19.8) 590 (22.8)
(continued)
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Table II. (continued).
Linagliptin Placebo
Calcium antagonists 824 (17.1) 472 (18.2)
Diuretics 742 (15.4) 497 (19.2)
Combinations 531 (11.0) 290 (11.2)
Other 10 (0.2) 8 (0.3)
Lipid-lowering drugs 1994 (41.5) 1173 (45.3)
P-glycoprotein or CYP 3A inhibitors 168 (3.5) 108 (4.2)
Patients receiving antidiabetes background medication
during treatment, no. (%)
0 1136 (23.6) 650 (25.1)
1 2044 (42.5) 996 (38.5)
Z2 1630 (33.9) 944 (36.4)
Insulin  other antidiabetes drug§ 788 (16.4) 796 (30.7)
SU  other antidiabetes drug§ 1056 (22.0) 414 (16.0)
Insulin þ SU  other antidiabetes drug§ 23 (0.5) 7 (0.3)
Metformin  other antidiabetes drug§ 2943 (61.2) 1416 (54.7)
Data are mean (SD) unless otherwise stated.
ACE ¼ angiotensin-converting enzyme; ARBs ¼ angiotensin II receptor blockers; BMI ¼ body mass index; CV ¼
cardiovascular; CYP 3A ¼ cytochrome P-450 3A; eGFR ¼ estimated glomerular ﬁltration rate; HbA1c ¼ glycosylated
hemoglobin; MDRD ¼ Modiﬁcation of Diet in Renal Disease; SU ¼ sulfonylurea; TS ¼ treated set.
*Fasting plasma glucose data converted from mg/dL to mmol/L using conversion factor of 0.0555.
†Microvascular disease includes diabetic retinopathy, nephropathy, and neuropathy.
‡Patients were permitted to take 41 CV medication, if required.
§Patients receiving 41 background therapy could be included in 41 count.
M. Lehrke et al.(3.2% [n ¼ 153] and 3.3% [n ¼ 83], respectively)
(Table IV). There was no apparent imbalance in heart
failure AEs (based on the preferred terms cardiac
failure, cardiac failure acute, and cardiac failure
congestive) among linagliptin-treated patients com-
pared with placebo-treated patients (0.2% [n ¼ 11]
and 0.3% [n ¼ 7], respectively). These data equate to
an incidence rate (per 1000 patient-years) of 0.45 for
linagliptin and 0.46 for placebo. A total of 8 of 11
patients receiving linagliptin experienced heart failure
that was recorded as being serious, 1 of which was
fatal, compared with 3 of 7 patients receiving placebo
(no fatal events). For the narrow standardized MedDRA
query of cardiac failure (code 20000004) (Table IV),
the incidence was 0.4% (n ¼ 21) and 0.3% (n ¼ 8) for
linagliptin and placebo, respectively. Tachycardia
(measured by counting the pulse and based on AE
reporting) occurred at a similar frequency among
linagliptin- and placebo-treated patients (0.2% and
0.1%, respectively) as did the reported AEs ofAugust 2014arrhythmia (both 0.1%) and hypertension (2.3%
and 2.8%, respectively). Ischemic cardiac events de-
ﬁned using MedDRA version 15.1 also occurred at
levels o1.0% and at similar rates for linagliptin- and
placebo-treated patients (Table IV).
Hepatobiliary AEs were reported infrequently for
both the linagliptin and placebo groups (both 0.9%).
Renal and urinary AEs were reported with a similar
frequency for both the linagliptin and placebo groups
(3.5% and 4.4%, respectively).
Overall, linagliptin was weight neutral, with no
evidence of an increased incidence of AE reports of
weight gain with linagliptin versus placebo (both 0.2%).
Hypoglycemia
The overall proportion of patients experiencing
investigator-deﬁned hypoglycemic AEs was signiﬁ-
cantly lower for linagliptin (11.5%) versus placebo
(14.0%) (Figure A). This equated to an exposure-
adjusted incidence rate (per 1000 patient-years) of1137
Table III. Frequency of AEs among patients who received linagliptin or placebo (TS).
AEs Linagliptin (n ¼ 4810) Placebo (n ¼ 2590)
Any AE 2758 (57.3) 1601 (61.8)
Drug-related AEs 562 (11.7) 354 (13.7)
AEs leading to discontinuation of trial drug 141 (2.9) 107 (4.1)
Serious AEs* 230 (4.8) 167 (6.4)
Fatal AEs 10 (0.2) 9 (0.3)
AE ¼ adverse events; TS ¼ treated set.
Data are number (%).
*Serious AEs that were considered to be drug-related: 13 (0.3%) and 3 (0.1%), for linagliptin and placebo, respectively.
Clinical Therapeutics25.5 and 28.1, respectively. The proportion of patients
experiencing severe hypoglycemia, requiring assistance,
was similar in both groups (linagliptin, 0.4%; placebo,
0.5%). However, it should be noted that the percentage
of patients receiving background therapy with SU or
insulin ( other antidiabetes therapies) was slightly
greater among placebo-treated patients (1210, 46.7%)
than linagliptin-treated patients (1844, 38.3%)
(with similar percentages receiving both SU þ insulin
[ other antidiabetes therapies] in both groups
[0.3% and 0.5%, respectively]) (Table II). Furthermore,
the percentage of patients who received antidiabetic
rescue medication during the study was approximately
twice as high in the placebo group (22.3%) compared
with those receiving linagliptin (10.5%).
Of the 553 patients receiving linagliptin who reported
an investigator-deﬁned hypoglycemic AE, 43.0% (238)
were receiving concomitant SU therapy. Among patients
receiving concomitant SU therapy, investigator-deﬁned
hypoglycemic AEs were more frequent, occurring in
22.1% (238/1079) of linagliptin- and 14.5% (61/421) of
placebo-treated patients (Figure B). In contrast, the
incidence of investigator-deﬁned hypoglycemic AEs for
linagliptin- and placebo-treated patients was similar for
those receiving insulin during the treatment phase:
35.5% (288/811) and 36.0% (289/803), respectively,
with a risk ratio of hypoglycemia for linagliptin versus
placebo of 0.99 (95% CI, 0.87–1.21; P ¼ 0.8762).Subgroup Analyses
Analyses of the effect of age on the safety of
linagliptin showed that treatment was well tolerated
across all age groups, with a low incidence of
investigator-deﬁned hypoglycemic AEs (Table V). The1138overall incidence of AEs and AEs by system organ class
was similar for linagliptin and placebo. As expected,
advancing age was associated with a numerical increase
in the incidence of AEs, but the incidences of AEs,
including fatal events, for patients receiving linagliptin
and placebo remained similar (Table V, Figure).
Similarly, there was a small age-related increase in the
frequency of cardiac ischemic events and heart failure,
although the number of events was small, and frequen-
cies were similar for linagliptin- and placebo-treated
patients. A similar pattern was observed for the
incidence of hypoglycemic events by age (Figure C).
Analyses of safety data by renal function showed
that linagliptin was associated with a similar AE
proﬁle in patients with and without renal impairment
(Table V). The overall number of patients with AEs
increased numerically with declining renal function,
although the incidences of AEs, including fatal events,
were similar for patients receiving linagliptin and
placebo within each renal function subgroup. A
similar pattern was observed for the incidence of
hypoglycemic events by renal function (Figure D).DISCUSSION
The ﬁndings of this updated and expanded post hoc
pooled analysis of all currently available placebo-
controlled trials of linagliptin (22 studies), which
included a total of 7400 patients exposed to linagliptin
or placebo, provides further evaluation of the overall
safety proﬁle of linagliptin. This analysis supports the
ﬁndings of previous studies, showing that the safety
proﬁle for linagliptin is consistent with the adverse
effects listed in the current prescribing information for
linagliptin.9 The subgroup analyses conducted showVolume 36 Number 8
Table IV. Summary of AEs by system organ class in overall population (TS).
AEs Linagliptin (n ¼ 4810) Placebo (n ¼ 2590)
Blood and lymphatic system disorders (2.1) (2.2)
Cardiac disorders* 153 (3.2) 85 (3.3)
Arrhythmia 4 (0.1) 2 (0.1)
Tachycardia 11 (0.2) 3 (0.1)
Cardiac events
Acute coronary syndrome 3 (0.1) 2 (0.1)
Acute myocardial infarction 7 (0.1) 4 (0.2)
Angina pectoris 22 (0.5) 13 (0.5)
Unstable angina 4 (0.1) 4 (0.2)
Cardiac arrest 2 (o0.1) 0 (0.0)
Myocardial infarction 9 (0.2) 3 (0.1)
Myocardial ischemia 11 (0.2) 4 (0.2)
Silent myocardial infarction 1 (o0.1) 0 (0.0)
Narrow SMQ cardiac failure 21 (0.4) 8 (0.3)
Acute cardiac failure† 2 (o0.1) 0 (0.0)
Acute pulmonary edema† 1 (o0.1) 1 (o0.1)
Cardiac failure† 6 (0.1) 2 (0.1)
Cardiogenic shock† 1 (o0.1) 0 (0.0)
Congestive cardiac failure† 5 (0.1) 5 (0.2)
Left ventricular failure† 6 (0.1) 0 (0.0)
Pulmonary edema† 1 (o0.1) 2 (0.1)
Right ventricular failure† 1 (o0.1) 0 (0.0)
Congenital, familial, and genetic disorders 2 (o0.1) 1 (o0.1)
Ear and labyrinth disorders 50 (1.0) 28 (1.1)
Endocrine disorders 17 (0.4) 10 (0.4)
Eye disorders 158 (3.3) 87 (3.4)
Gastrointestinal disorders 548 (11.4) 33 (12.7)
Diarrhea 132 (2.7) 77 (3.0)
Pancreatitis 2 (o0.1) 1 (o0.1)
Chronic pancreatitis 3 (0.1) 0 (0.0)
General disorders and administration site conditions 286 (5.9) 181 (7.0)
Hepatobiliary disorders 42 (0.9) 23 (0.9)
Immune system disorders 14 (0.3) 10 (0.4)
Drug hypersensitivity 4 (0.1) 1 (o0.1)
Infections and infestations 1025 (21.3) 648 (25.0)
Inﬂuenza 80 (1.7) 60 (2.3)
Nasopharyngitis 281 (5.8) 155 (6.0)
Upper respiratory tract infection 159 (3.3) 111 (4.3)
Urinary tract infection 144 (3.0) 106 (4.1)
Injury, poisoning, and procedural complications 249 (5.2) 148 (5.7)
Investigations 260 (5.4) 167 (6.4)
Amylase increased 14 (0.3) 4 (0.2)
Metabolism and nutrition disorders 988 (20.5) 721 (27.8)
Hyperglycemia 319 (6.6) 330 (12.7)
(continued)
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Table IV. (continued).
AEs Linagliptin (n ¼ 4810) Placebo (n ¼ 2590)
Hypoglycemia 532 (11.1) 349 (13.5)
Musculoskeletal and connective tissue disorders 540 (11.2) 315 (12.2)
Arthralgia 98 (2.0) 60 (2.3)
Back pain 118 (2.5) 79 (3.1)
Neoplasms benign, malignant, and unspeciﬁed 29 (0.6) 24 (0.9)
Pancreatic cancer 0 (0.0) 0 (0.0)
Nervous system disorders 389 (8.1) 248 (9.6)
Dizziness 114 (2.4) 64 (2.5)
Headache 148 (3.1) 85 (3.3)
Cerebral ischemia 1 (o0.1) 2 (0.1)
Cerebrovascular accident 4 (0.1) 3 (0.1)
Ischemic stroke 0 (0.0) 2 (0.1)
Transient ischemic attack 2 (o0.1) 2 (0.1)
Pregnancy, puerperium, and perinatal conditions 0 (0.0) 1 (o0.1)
Psychiatric disorders 87 (1.8) 76 (2.9)
Renal and urinary disorders 170 (3.5) 114 (4.4)
Reproductive system and breast disorders 55 (1.1) 45 (1.7)
Respiratory, thoracic, and mediastinal disorders 229 (4.8) 129 (5.0)
Cough 95 (2.0) 51 (2.0)
Skin and subcutaneous tissue disorders 217 (4.5) 131 (5.1)
Social circumstances‡ 0 (0.0) 1 (o0.1)
Surgical and medical procedures 25 (0.5) 18 (0.7)
Vascular disorders* 182 (3.8) 114 (4.4)
Hypertension 113 (2.3) 73 (2.8)
AE ¼ adverse event; TS ¼ treated set.
Data are number (%).
Subcategories shown if incidence in either group wasZ2% or was a selected AE of interest. AEs are reported as system organ
classes and preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA) version 15.1.
*The System Organ Classes, cardiac disorders and vascular disorders are grouped by manifestation site. The cardiac disorders
class includes conditions such as coronary artery disease, heart failure, arrhythmias, and valve disorders; vascular disorders
includes hypo- and hypertension, deep venous thrombosis, peripheral arterial disease, and arteriosclerosis.
†These preferred terms are included in the standardized Medical Dictionary for Regulatory Activities query (SMQ) for heart
failure.
‡Refers to 1 incidence of menopause reported in the placebo group.
Clinical Therapeuticsthat the safety and tolerability of linagliptin, including
the risk of hypoglycemia, is not adversely affected by
increasing age or declining renal function.
Overall, the reported AEs were of similar incidence
for linagliptin- and placebo-treated patients (overall
AEs, 57.3% and 61.8%, respectively), with similar
incidences of serious AEs and drug-related AEs.
Furthermore, there were no apparent differences
between the linagliptin and placebo groups for the1140AEs that were most frequently reported, including
infections, musculoskeletal disorders, nervous system
disorders, and gastrointestinal disorders.
Given the similarity in AE proﬁles for linagliptin and
placebo reported in this analysis and in previous
studies,16,18,19,41 some speciﬁc trends observed may
likely be attributed to factors beyond the studied
medication. For example, the relatively high frequency
of infections across the population as a whole isVolume 36 Number 8
Table V. Frequency of investigator-reported AEs, including investigator-defined hypoglycemic events, by age
(years) and renal function (eGFR), for linagliptin versus placebo (TS).
Linagliptin Placebo Linagliptin Placebo Linagliptin Placebo
Age o65 y Age 65–74 y Age Z75 y
No. 3389 1789 1153 647 268 154
Any AE, no. (%) 1878 (55.4) 1062 (59.4) 700 (60.7) 427 (66.0) 180 (67.2) 112 (72.7)
Drug-related AEs 352 (10.4) 201 (11.2) 163 (14.1) 123 (19.0) 47 (17.5) 30 (19.5)
SAEs, no. (%) 141 (4.2) 81 (4.5) 68 (5.9) 59 (9.1) 21 (7.8) 27 (17.5)
Fatal events, no. (%) 7 (0.2) 5 (0.3) 3 (0.3 ) 2 (0.3) 0 (0.0) 2 (1.3)
No. 3389 1789 1153 647 268 154
Hypoglycemia, no. (%) 322 (9.5) 187 (10.5) 172 (14.9) 140 (21.6) 59 (22.0) 35 (22.7)
eGFR Z90 eGFR 60–90 eGFR o60
No. 1918 955 2263 1198 619 422
Any AE, no. (%) 1035 (54.0) 545 (57.1) 1281 (56.6) 731 (61.0) 436 (70.4) 319 (75.6)
Drug-related AEs 167 (8.7) 89 (9.3) 270 (11.9) 161 (13.4) 125 (20.2) 101 (23.9)
SAEs, no. (%) 60 (3.1) 42 (4.4) 104 (4.6) 60 (5.0) 66 (10.7) 65 (15.4)
Fatal events, no. (%) 1 (0.1) 2 (0.2) 3 (0.1) 1 (0.1) 6 (1.0) 6 (1.4)
No. 1918 955 2263 1198 619 422
Hypoglycemia, no. (%) 159 (8.3) 71 (7.4) 235 (10.4) 157 (13.1) 159 (25.7) 133 (31.5)
AE ¼ adverse event; eGFR ¼ estimated glomerular ﬁltration rate; SAE ¼ serious adverse event; TS ¼ treated set.
An SAE was deﬁned as an event that was fatal or life-threatening, required in-patient hospitalization or prolonged existing
hospitalization, resulted in persistent or signiﬁcant disability/incapacity, was a congenital anomaly/birth defect, or was
deemed serious for any other reason.
M. Lehrke et al.consistent with the presence of T2DM, and the fre-
quency of diarrhea, a common side effect of metformin
therapy, is consistent with the high level of background
metformin therapy (alone or with other background
therapies) used by the study participants (61.2% of
linagliptin- and 54.7% of placebo-treated patients).
The incidence of hypoglycemia was low among
patients receiving linagliptin and did not appear to
increase, relative to placebo, by advancing age or
declining renal function or by background insulin
therapy. Interestingly, the overall incidence of
investigator-deﬁned hypoglycemic AEs was signiﬁ-
cantly lower with linagliptin therapy than for placebo.
At present, the explanation for the signiﬁcantly lower
frequency of investigator-deﬁned hypoglycemic events
for linagliptin- versus placebo-treated patients is un-
clear. Further research is warranted to evaluate the
similar incidence of hypoglycemia with linagliptin;
conducting an analysis with exclusion of reports ofAugust 2014hypoglycemic events after glycemic rescue therapy
would be an appropriate initial approach. It is
interesting to note that data from other incretin-
based therapies indicate that this is likely to involve
an enhancement of islet responsiveness (both α and
β cell) to hypoglycemia,42,43 potentially mediated
through an increase in GIP levels.44 However, it is
also important to emphasize that the incidence of
hypoglycemia is increased when linagliptin is given on
a background of SU versus linagliptin plus placebo.
This effect on hypoglycemia has been demonstrated
with all incretin-based therapies and is thought to be
due to a pharmacodynamic interaction whereby SU
therapy uncouples the insulinotropic action of GLP-1
from its glucose dependence.45 An increase in the risk
of hypoglycemia is well known with SU therapy
and an increase in hypoglycemic events has been
reported when these agents are used in combination
with other antihyperglycemic drugs, such as metformin1141
Clinical Therapeuticsand GLP-1 agonists.46,47 Adjustment of SU therapy to
a lower dose should, therefore, be considered when
adding linagliptin to pre-existing SU therapy. This is
recommended in the prescribing information for lina-
gliptin9 and other DPP-4 inhibitors.48,49
Recent studies indicated a possible link between
incretin-based therapies and an elevated risk of the
development of acute pancreatitis or pancreatic can-
cer.50,51 Pancreatitis is listed as an adverse reaction
associated with linagliptin therapy, as listed in the
prescribing information.9 This is further emphasized
in the product labeling, which states that treatment
should be discontinued if pancreatitis is suspected. The
present pooled post hoc analysis demonstrates a low
incidence of pancreatitis and shows similar incidences
of pancreatic malignancy with linagliptin therapy and
placebo. The number of events in this patient
population, however, is too small for in-depth safety
evaluations of very rare events such as pancreatitis or
cancer. It is likely that pharmacoepidemiological ap-
proaches will be needed to fully address this question.
A cardiovascular (CV) risk assessment of linagliptin
has been performed in 2 prespeciﬁed analyses, both of
which have not shown an increase in CV risk associated
with linagliptin therapy.52,53 Similarly, reassuring ﬁnd-
ings have emerged from the randomized CV outcome
trials, EXAMINE (EXamination of CArdiovascular
outcoMes: AlogliptiN versus Standard of carE in
patients with type 2 diabetes mellitus and acute coro-
nary syndrome) and SAVOR-TIMI 53 (The Saxagliptin
Assessment of Vascular Outcomes Recorded in patients
with diabetes mellitus [SAVOR] - Thromboloysis In
Myocaridal Infadcrtion [TIMI]). EXAMINE was de-
signed to investigate whether major CV event rates were
higher with alogliptin compared with placebo therapy
in patients with T2DM and recent acute coronary
syndrome.54 After a median follow-up period of 1.5
years, similar rates of major CV AEs in addition to CV
or all-cause mortality were reported for patients allo-
cated to alogliptin or placebo. The SAVOR-TIMI 53
trial evaluated the effects of saxagliptin on CV outcomes
in T2DM patients at high CV risk. No difference in the
primary composite endpoint of CV death, myocardial
infarction, or ischemic stroke was found in saxagliptin-
or placebo-treated patients.55 An unexpected ﬁnding of
this trial was an increased incidence of hospital
admissions for chronic heart failure in patients
receiving saxagliptin, whereas no difference in heart
failure-related death was reported. Similarly, a trend1142toward an increased risk of hospital admission for
chronic heart failure was also found in the EXAMINE
trial.56 These ﬁndings merit further evaluation. No
apparent increased risk of heart failure with linagliptin
was found in the current pooled analysis, although it is
not possible to draw deﬁnitive conclusions from these
data, as the number of events was small.
In view of the xanthine-based structure of linaglip-
tin and the known relationship between other xan-
thine derivatives and cardiac effects such as
tachycardia and arrhythmias, the impact of linagliptin
therapy on these AEs is of interest. At present, there
are no data to suggest an increased risk of these events
with linagliptin therapy.
As with all pooled analyses, the present study is
limited by the use of data from different clinical studies,
as well as the relatively short duration of the included
studies. In addition, no inferential statistics were de-
rived, except for the analysis of hypoglycemia. How-
ever, this analysis was based on individual patient data
from a consistently designed, large clinical development
program, so methodological differences between indi-
vidual trials were small. Furthermore, the use of pooled
patient-level data provides a more sensitive evaluation
of research ﬁndings than meta-analysis of trial-level
data, which only reports whether an event has occurred
in a trial. The robustness of the ﬁndings of the present
study is further supported by the consistency of the
results obtained across the individual trials.
The duration and timing of intervention, in addi-
tion to the presence of concomitant conditions and the
stage of T2DM, likely inﬂuence outcomes in the
management of patients with T2DM. Thus, ongoing
trials have been uniquely designed to further evaluate
the long-term safety and potential beneﬁts of linaglip-
tin in high-risk patient groups exhibiting a higher CV
risk compared with the patients included in the
present analysis. With regard to CV outcomes, the
effect of linagliptin on CV endpoints is currently
under evaluation in the CAROLINA® (CARdiovascu-
lar Outcome Study of LINAgliptin versus Glime-
piride in Patients with Type 2 Diabetes trial)
(NCT01243424), which includes patients with early
T2DM identiﬁed as being at moderate risk of CV
disease, with a proportion of these having previous
CV disease. This is the only head-to-head CV outcome
trial of a DPP-4 inhibitor versus active comparator that
is sufﬁciently powered to assess CV events (targeting
time to ﬁrst occurrence of 631 CV death, non-fatalVolume 36 Number 8
M. Lehrke et al.stroke, non-fatal myocardial infarction or hospitaliza-
tion for unstable angina).57 A second cardiorenal
outcome study, which started in the middle of 2013,
the CARMELINA® (CARdiovascular Safety & Clinical
outcoME with LINAgliptin) trial (NCT01897532), will
compare the CV and renal safety of linagliptin versus
placebo, when added to standard care in patients with
T2DM at high CV risk. Adults with T2DM and
evidence of renal impairment, with or without
previous CV complications, or with albuminuria
(urine albumin-to-creatinine ratio Z30 mg/g) plus
evidence of CV complications, will be randomized
into the study. CARMELINA is the only study of
DPP-4 inhibitors to explore both macrovascular (tar-
geting 625 4P-major adverse cardiac events [4-compo-
nent composite endpoint: CV death, stroke, myocardial
infarction, or unstable angina pectoris with hospital-
ization]) and microvascular (targeting time to ﬁrst
occurrence of 625 CV death, non-fatal stroke, non-
fatal myocardial infarction or hospitalization for un-
stable angina) endpoints, and its ﬁndings will provide
important clinical guidance. Both of these studies will
also assess the impact of linagliptin therapy on heart
failure, and other important safety endpoints, including
pancreatitis, malignancies, severe hypersensitivity reac-
tions, and renal or hepatic AEs.
CONCLUSIONS
The ﬁndings of this updated and expanded, post hoc
pooled analysis of all currently available placebo-
controlled trials of linagliptin 5 mg daily support
previous ﬁndings that have demonstrated an accept-
able safety proﬁle with respect to the overall safety
and tolerability of linagliptin when administered to a
broad range of patients with T2DM. In the present
analysis, linagliptin-treated patients were shown to
have a low overall incidence of hypoglycemia
(although this incidence was increased by concomitant
SU therapy). Furthermore, the tolerability of linaglip-
tin did not appear to be altered by increasing age or
decreasing renal function. The results of ongoing
clinical trials, such as CAROLINA and CARME-
LINA, will provide additional insight into the long-
term safety and tolerability of linagliptin.
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